Drug Trial Radar · NCT07132957
A Study of AL8326 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Feb 21, 2025
Primary completion
May 17, 2025
Study completion May 17, 2025
Sponsor
- Lead sponsor
- Advenchen Laboratories Nanjing Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This experiment plans to enroll 6-8 healthy male subjects in China, and ultimately collect complete test samples and data from at least 6 subjects as the standard. On the first day of the experiment, each subject orally took a single dose of \[14C\] AL8326 oral formulation containing approximately 60mg (200 μ Ci). During the experiment, whole blood, plasma, urine, and fecal samples were collected at designated time points/time periods.
Conditions
- Small Cell Lung Cancer
- Solid Tumors
Interventions
14C-labeled AL8326Drug
Oral, About 60mg (200μCi) of 14C-labeled AL8326
Primary outcomes
What the sponsor says the trial is designed to measure.
- Material balanceTime frame: All excreted urine and feces samples at specified time points during 0-480 hours after dosing will be collected.
- MetabolitesTime frame: Conduct testing within 1 month after all subjects collect plasma, urine, and fecal samplesat all time points required by the protocol
- MetabolitesTime frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol
- PharmacokineticTime frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol
- whole bloodTime frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.